Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
Julie K. Casteel, Chief Sales/Marketing Officer at IBEX Ltd (NASDAQ:IBEX), sold 5,000 shares of the company’s common stock on September 16, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as IBEX shares have surged nearly 40% in the past week and more than doubled over the last year.
The shares were sold at a price of $39.0002, for a total transaction value of $195,001. Following the transaction, Casteel directly owns 25,895 shares of IBEX Ltd. According to InvestingPro analysis, the stock’s RSI indicates overbought conditions, though the company maintains a "GREAT" financial health score. For deeper insights into IBEX’s valuation and 17 additional ProTips, including management’s share buyback activities, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, IBEX Ltd. reported strong financial results for the fourth quarter of 2025, surpassing market expectations. The company achieved earnings per share of $0.87, exceeding the forecasted $0.70. Revenue for the quarter reached $147.1 million, significantly higher than the anticipated $129.21 million. This performance marks a notable improvement and highlights the company’s accelerated revenue growth. RBC Capital responded by raising its price target for IBEX to $39.00 from $31.00, maintaining a Sector Perform rating. RBC attributed the target increase to the company’s sustainable growth, driven by existing clients and geographic expansion with its second-largest client. These developments reflect positively on IBEX’s financial health and growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.